Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€1.86
23.04.16
€18.58
22.10.24
40.44%
24.01.23

Subdi 
14.08.19 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.44
17.10.22
-
17.10.23
-7.41%
22.12.22

Risky Investment
bundfuture 
17.10.22 50%
buy
Aptose Biosciences

Start price
Target price
Perf. (%)
€0.98
14.12.21
-
14.12.22
-39.08%
15.12.22

Could be worthwhile Investment >10% per year
melinda 
14.12.21 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€8.47
13.12.21
-
13.12.22
-67.06%
14.12.22

Could be very worthwhile Investment >20% year
Revenue decline/stagnation expected
robertinio 
13.12.21 100%
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€4.85
01.12.21
-
01.12.22
-53.67%
02.12.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Maxi_Scalibusa 
01.12.21 0%
sell
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.05
20.09.22
€1.80
20.09.23
36.59%
19.11.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
geldnutzer 
20.09.22 50%
sell
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.55
13.10.22
€2.30
13.10.23
42.55%
19.11.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
geldnutzer 
13.10.22 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€13.55
13.11.21
-
13.11.22
-69.88%
14.11.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
Maxi_Scalibusa 
13.11.21 0%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.91
03.08.22
€3.30
03.08.23
-12.37%
13.10.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
geldnutzer 
03.08.22 50%
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.39
03.08.22
€2.80
03.08.23
-14.19%
20.09.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
geldnutzer 
03.08.22 50%
sell
Burcon Nutrascience Corp.

Start price
Target price
Perf. (%)
€1.53
19.09.21
-
19.09.22
-75.74%
20.09.22

Probably not worthwhile Investment
Lokrim 
19.09.21 10%
buy
Acasti Pharma Inc.

Start price
Target price
Perf. (%)
€11.77
12.09.21
€15.00
12.09.22
-60.64%
13.09.22

Could be worthwhile Investment >10% per year
melinda 
12.09.21 50%
buy
Bausch Health Companies Inc.

Start price
Target price
Perf. (%)
€5.40
23.08.22
-
23.08.23
29.96%
09.09.22

Capable Management
Probably not worthwhile Investment
Revenue decline/stagnation expected
efeu 
23.08.22 50%
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€7.85
24.08.22
-
24.08.23
-10.03%
03.09.22

Could be worthwhile Investment >10% per year
Vassago1 
24.08.22 50%
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€10.81
04.07.22
-
04.07.23
-24.63%
06.08.22

Could be worthwhile Investment >10% per year
Vassago1 
04.07.22 50%
sell
Bausch Health Companies Inc.

Start price
Target price
Perf. (%)
€8.45
11.07.22
-
11.07.23
-39.77%
04.08.22

Capable Management
Probably not worthwhile Investment
Revenue decline/stagnation expected
efeu 
11.07.22 50%
sell
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.37
28.04.22
€2.00
28.04.23
0.74%
03.08.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
geldnutzer 
28.04.22 50%
sell
Canopy Growth Corp

Start price
Target price
Perf. (%)
€3.50
11.06.22
€1.90
11.06.23
-16.96%
03.08.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
geldnutzer 
11.06.22 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€3.50
12.06.22
-
12.06.23
-26.05%
09.07.22

Could be very worthwhile Investment >20% year
thomasw 
12.06.22 50%
buy
Emerald Health Therapeutics Inc

Start price
Target price
Perf. (%)
€0.13
08.07.21
-
08.07.22
-77.81%
08.07.22

Maxi_Scalibusa 
08.07.21 50%
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.39
08.07.21
-
08.07.22
13.98%
08.07.22

Joe130978 
08.07.21 50%
buy
Organigram Holdings Inc.

Start price
Target price
Perf. (%)
€9.52
27.05.21
€32.00
27.05.22
-55.61%
28.05.22

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Very Future proof/growth oriented business model
Branding999 
27.05.21 80%
buy
Antibe Therapeutics Inc.

Start price
Target price
Perf. (%)
€2.48
08.07.21
-
08.07.22
-80.56%
21.05.22

Lector 
08.07.21 50%
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€5.70
18.04.22
-
18.04.23
-3.95%
30.04.22

Could be very worthwhile Investment >20% year
thomasw 
18.04.22 50%
buy
Organigram Holdings Inc.

Start price
Target price
Perf. (%)
€4.96
07.03.22
-
07.03.23
27.52%
28.03.22

Could be worthwhile Investment >10% per year
robertinio 
07.03.22 100%